

Maximilian Mossner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2275291/publications.pdf>

Version: 2024-02-01

62
papers

2,796
citations

471509

17
h-index

265206

42
g-index

69
all docs

69
docs citations

69
times ranked

4716
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Control of HIV by <i>CCR5</i> Δ32/Δ32 Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2009, 360, 692-698.	27.0	1,655
2	Myelodysplastic Cells in Patients Reprogram Mesenchymal Stromal Cells to Establish a Transplantable Stem Cell Niche Disease Unit. <i>Cell Stem Cell</i> , 2014, 14, 824-837.	11.1	335
3	Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. <i>Blood</i> , 2016, 128, 1246-1259.	1.4	111
4	Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. <i>Clinical Microbiology and Infection</i> , 2016, 22, 862-868.	6.0	78
5	Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. <i>Haematologica</i> , 2009, 94, 1383-1390.	3.5	70
6	Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. <i>Blood</i> , 2011, 118, 4174-4178.	1.4	58
7	Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS). <i>Leukemia</i> , 2016, 30, 1956-1959.	7.2	55
8	SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. <i>Blood</i> , 2010, 115, 1049-1053.	1.4	38
9	Reconstructing single-cell karyotype alterations in colorectal cancer identifies punctuated and gradual diversification patterns. <i>Nature Genetics</i> , 2021, 53, 1187-1195.	21.4	37
10	Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS. <i>Leukemia Research</i> , 2010, 34, 1610-1616.	0.8	33
11	Activating CBL mutations are associated with a distinct MDS/MPN phenotype. <i>Annals of Hematology</i> , 2012, 91, 1713-1720.	1.8	29
12	Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL. <i>Journal of Hematology and Oncology</i> , 2016, 9, 95.	17.0	23
13	Epigenetic dysregulation of <i>GATA1</i> is involved in myelodysplastic syndromes dyserythropoiesis. <i>European Journal of Haematology</i> , 2012, 88, 144-153.	2.2	21
14	Skewed X-inactivation patterns in ageing healthy and myelodysplastic haematopoiesis determined by a pyrosequencing based transcriptional clonality assay. <i>Journal of Medical Genetics</i> , 2013, 50, 108-117.	3.2	21
15	Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia. <i>Leukemia Research</i> , 2011, 35, 614-619.	0.8	20
16	Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance. <i>Experimental Hematology</i> , 2015, 43, 32-43.e35.	0.4	20
17	Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy. <i>Experimental Hematology</i> , 2009, 37, 215-224.e2.	0.4	17
18	Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia. <i>Leukemia Research</i> , 2009, 33, 817-822.	0.8	17

#	ARTICLE	IF	CITATIONS
19	Expression of <i>IGFBP7</i> in acute leukemia is regulated by DNA methylation. <i>Cancer Science</i> , 2011, 102, 253-259.	3.9	17
20	Measurement of mechanical properties of snow for simulation of skiing. <i>Journal of Glaciology</i> , 2013, 59, 1170-1178.	2.2	17
21	SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 756-767.	2.8	16
22	Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo. <i>Nature Communications</i> , 2021, 12, 6170.	12.8	14
23	Centrosome aberrations in bone marrow cells from patients with myelodysplastic syndromes correlate with chromosomal instability. <i>Annals of Hematology</i> , 2013, 92, 1325-1333.	1.8	11
24	MDS-Derived Stromal Cells Exhibit Altered Gene Expression and Support The Engraftment Of lin-CD34+CD38- Disease-Initiating Stem Cells In a Xenograft Model Of Lower Risk MDS. <i>Blood</i> , 2013, 122, 100-100.	1.4	11
25	Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS. <i>Leukemia Research</i> , 2018, 68, 62-69.	0.8	10
26	Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, e247-e248.	3.5	7
27	LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations. <i>IScience</i> , 2021, 24, 102889.	4.1	6
28	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. <i>Blood</i> , 2013, 122, 743-743.	1.4	6
29	Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer. <i>Oncotarget</i> , 2017, 8, 84714-84728.	1.8	5
30	High erythroferrone expression in CD71 + erythroid progenitors predicts superior survival in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2021, 192, 879-891.	2.5	4
31	Detection of differential mitotic cell age in bone marrow CD34+ cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature. <i>Experimental Hematology</i> , 2010, 38, 661-665.	0.4	3
32	[Letter to the editor] Whole-genome amplification of sodium bisulfite-converted DNA can substantially impact quantitative methylation analysis using pyrosequencing. <i>BioTechniques</i> , 2011, 50, 161-164.	1.8	3
33	Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 411-417.	2.5	3
34	Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects. <i>European Journal of Haematology</i> , 2017, 98, 302-310.	2.2	3
35	Gene Expression of the Erythroid Regulator Erythroferrone (ERFE) is Highly Deregulated in CD71+ Erythropoietin Cells of Patients with Myelodysplastic Syndromes and Demonstrates Prognostic Relevance. <i>Blood</i> , 2014, 124, 4620-4620.	1.4	3
36	The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study. <i>Blood</i> , 2014, 124, 4669-4669.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study. <i>Blood</i> , 2016, 128, 228-228.	1.4	2
38	Comparative analysis of clonal hematopoiesis of multipotent stem cells in healthy elderly in blood and bone marrow. <i>Leukemia Research</i> , 2019, 82, 15-18.	0.8	1
39	The role of single-cell sequencing in studying tumour evolution. <i>Faculty Reviews</i> , 2021, 10, 49.	3.9	1
40	The Pax5 Fusion Product Pax5-C20orf112 Causes Downregulation of Pre-B Cell Receptor Genes and Induces Differential Proliferation Patterns in B-Lymphoblastic Cell Lines.. <i>Blood</i> , 2009, 114, 1284-1284.	1.4	1
41	Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment. <i>Blood</i> , 2015, 126, 2891-2891.	1.4	1
42	Next Generation RNA Sequencing of Acute Promyelocytic Leukemia (APL) Identifies Novel Long Non Coding RNAs Including New Variants of MIR181A1HG That Are Differentially Expressed during Myeloid Differentiation. <i>Blood</i> , 2014, 124, 1031-1031.	1.4	1
43	P069 Genome-wide DNA-mapping of CD34+ cells from MDS patients with 500K SNP arrays identifies significant regions of genomic alterations. <i>Leukemia Research</i> , 2007, 31, S77.	0.8	0
44	65 MYELODYSPLASTIC SYNDROMES ARE CHARACTERIZED BY RECURRENT PATTERNS IN PATIENT-INDIVIDUAL MUTATIONAL HIERARCHIES THAT ARE SUBJECT TO HIGHLY DYNAMIC SUBCLONAL EVOLUTION DURING THERAPY AND DISEASE PROGRESSION. <i>Leukemia Research</i> , 2015, 39, S32.	0.8	0
45	Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. <i>Journal of Medical Genetics</i> , 2017, 54, 640-650.	3.2	0
46	Next-Generation Bisulfite Sequencing Of Cacna1c With Illumina Miseq. <i>European Neuropsychopharmacology</i> , 2017, 27, S445.	0.7	0
47	High Density SNP Array Analysis of Acute Promyelocytic Leukemia (APL) Detects New Common Genomic Copy Number Alterations as Possible Cooperating Lesions. <i>Blood</i> , 2010, 116, 2721-2721.	1.4	0
48	Genome Wide DNA Methylation Analysis Identifies a Characteristic Methylation Profile for Patients with Acute Promyelocytic Leukemia and FLT3-Internal Tandem Duplication. <i>Blood</i> , 2012, 120, 3521-3521.	1.4	0
49	Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups. <i>Blood</i> , 2012, 120, 3801-3801.	1.4	0
50	Significant Engraftment of Immature Hematopoietic Cells From Patients with Low Risk Myelodysplastic Syndromes (MDS) in Immunodeficient Mice. <i>Blood</i> , 2012, 120, 1694-1694.	1.4	0
51	Molecular Characterization Of The Anti-Leukemic Effects Of Single Agent Eltrombopag. <i>Blood</i> , 2013, 122, 4923-4923.	1.4	0
52	Next Generation Sequencing-Based Molecular Dissection Of Lineage-Specific Mutational Hierarchies In Oligoclonal Primary and Xenografted Myelodysplasia. <i>Blood</i> , 2013, 122, 519-519.	1.4	0
53	The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2013, 122, 1562-1562.	1.4	0
54	TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial. <i>Blood</i> , 2013, 122, 2759-2759.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Array-Based Integrative Analysis Of Epigenomic and Transcriptomic Alterations In CD71+ Bone Marrow Erythroprogenitor Cells From Patients With Myelodysplastic Syndromes. <i>Blood</i> , 2013, 122, 1561-1561.	1.4	0
56	Quantitative Analysis of Patient-Specific Lesions in Primary and Xenografted Myelodysplastic Syndromes Reveals Complex Hierarchies and Subclonal Diversity That Evolve during Disease Progression. <i>Blood</i> , 2014, 124, 4604-4604.	1.4	0
57	Development of a DNA-Based Targeted Assay Suitable for Accurate Quantification of Chromosomal Deletions in Myelodysplastic Syndromes with Deletion (5q) and Other Clonal Diseases. <i>Blood</i> , 2014, 124, 1925-1925.	1.4	0
58	Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial. <i>Blood</i> , 2014, 124, 1920-1920.	1.4	0
59	Whole Genome Sequencing of Azole-Resistant <i>Aspergillus Fumigatus</i> Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results. <i>Blood</i> , 2015, 126, 4325-4325.	1.4	0
60	Safety and efficacy of the CD95-ligand inhibitor APG101 in transfusion-dependent patients with low risk MDS: Interim results from a phase I study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18552-e18552.	1.6	0
61	RNA Sequencing of Bone Marrow Derived Mesenchymal Stromal Cells (MSCs) of Healthy Young, Healthy Old and Patients with Myelodysplastic Syndrome (MDS) Reveals Transcriptomic Changes upon Aging of the Niche and Onset of MDS. <i>Blood</i> , 2016, 128, 4300-4300.	1.4	0
62	Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated <i>In Vivo</i> . <i>Blood</i> , 2021, 138, 1514-1514.	1.4	0